5 results on '"Breous-Nystrom E"'
Search Results
2. The physiological interactome of TCR-like antibody therapeutics in human tissues.
- Author
-
Marrer-Berger E, Nicastri A, Augustin A, Kramar V, Liao H, Hanisch LJ, Carpy A, Weinzierl T, Durr E, Schaub N, Nudischer R, Ortiz-Franyuti D, Breous-Nystrom E, Stucki J, Hobi N, Raggi G, Cabon L, Lezan E, Umaña P, Woodhouse I, Bujotzek A, Klein C, and Ternette N
- Subjects
- Humans, Cell Line, Tumor, Antigens, Neoplasm, Receptors, Antigen, T-Cell metabolism, Antibodies, Peptides chemistry
- Abstract
Selective binding of TCR-like antibodies that target a single tumour-specific peptide antigen presented by human leukocyte antigens (HLA) is the absolute prerequisite for their therapeutic suitability and patient safety. To date, selectivity assessment has been limited to peptide library screening and predictive modeling. We developed an experimental platform to de novo identify interactomes of TCR-like antibodies directly in human tissues using mass spectrometry. As proof of concept, we confirm the target epitope of a MAGE-A4-specific TCR-like antibody. We further determine cross-reactive peptide sequences for ESK1, a TCR-like antibody with known off-target activity, in human liver tissue. We confirm off-target-induced T cell activation and ESK1-mediated liver spheroid killing. Off-target sequences feature an amino acid motif that allows a structural groove-coordination mimicking that of the target peptide, therefore allowing the interaction with the engager molecule. We conclude that our strategy offers an accurate, scalable route for evaluating the non-clinical safety profile of TCR-like antibody therapeutics prior to first-in-human clinical application., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
3. Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.
- Author
-
Kerns SJ, Belgur C, Petropolis D, Kanellias M, Barrile R, Sam J, Weinzierl T, Fauti T, Freimoser-Grundschober A, Eckmann J, Hage C, Geiger M, Ng PR, Tien-Street W, Manatakis DV, Micallef V, Gerard R, Bscheider M, Breous-Nystrom E, Schneider A, Giusti AM, Bertinetti-Lapatki C, Grant HS, Roth AB, Hamilton GA, Singer T, Karalis K, Moisan A, Bruenker P, Klein C, Bacac M, Gjorevski N, and Cabon L
- Subjects
- Animals, Female, HEK293 Cells, HeLa Cells, Humans, Immunotherapy methods, Mice, Antibodies, Bispecific adverse effects, Lab-On-A-Chip Devices statistics & numerical data, T-Lymphocytes immunology
- Abstract
Traditional drug safety assessment often fails to predict complications in humans, especially when the drug targets the immune system. Here, we show the unprecedented capability of two human Organs-on-Chips to evaluate the safety profile of T-cell bispecific antibodies (TCBs) targeting tumor antigens. Although promising for cancer immunotherapy, TCBs are associated with an on-target, off-tumor risk due to low levels of expression of tumor antigens in healthy tissues. We leveraged in vivo target expression and toxicity data of TCBs targeting folate receptor 1 (FOLR1) or carcinoembryonic antigen (CEA) to design and validate human immunocompetent Organs-on-Chips safety platforms. We discovered that the Lung-Chip and Intestine-Chip could reproduce and predict target-dependent TCB safety liabilities, based on sensitivity to key determinants thereof, such as target expression and antibody affinity. These novel tools broaden the research options available for mechanistic understandings of engineered therapeutic antibodies and assessing safety in tissues susceptible to adverse events., Competing Interests: SK Is a current employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells', CB, HG, KK Is a former employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells', DP Is a former employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers Method for Assessing a Compound Interacting with a Target on Epithelial Cells,, MK Is a current or former employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). RB Is a former employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers, Method for Assessing a Compound Interacting with a Target on Epithelial Cells', JS, TW, TF, AF, JE, MG, AS, AG, TS, CK, MB Employment, patents and ownership of stock with Roche. CH, VM, RG, MB, EB Employment and ownership of stock with Roche. PN is a former employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). WT is a current employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). DM Is a current employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). CB, AR Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells'. Employment, patents and ownership of stock with Roche. GH Is a current or former employee of and hold equity interests or options to obtain equity interests in (Emulate Inc). Is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers 'Method for Assessing a Compound Interacting with a Target on Epithelial Cells', AM is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers Method for Assessing a Compound Interacting with a Target on Epithelial Cells'. PB No competing interests declared, NG, LC is an inventor on a patent application (P16451EP00/16/912,391) submitted by Hoffmann-LaRoche and Emulate that covers Method for Assessing a Compound Interacting with a Target on Epithelial Cells'. Employment, patents and ownership of stock with Roche., (© 2021, Kerns et al.)
- Published
- 2021
- Full Text
- View/download PDF
4. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
- Author
-
Gombos RB, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, Breous-Nystrom E, Dupont C, Ward RA, Mundt C, Duckless B, Tang H, Findeis MA, Schuster A, Waight JD, Underwood D, Clarke C, Ritter G, Merghoub T, Schaer D, Wolchok JD, van Dijk M, Buell JS, Cuillerot JM, Stein R, Drouin EE, and Wilson NS
- Subjects
- Adjuvants, Immunologic chemistry, Adjuvants, Immunologic pharmacokinetics, Adjuvants, Immunologic toxicity, Amino Acid Sequence, Animals, Antibody Formation drug effects, Antineoplastic Agents, Immunological chemistry, Antineoplastic Agents, Immunological pharmacokinetics, Antineoplastic Agents, Immunological toxicity, CHO Cells, CTLA-4 Antigen antagonists & inhibitors, Cancer Vaccines pharmacology, Cells, Cultured, Cricetulus, Epitope Mapping, Humans, Immunity, Cellular drug effects, Immunoglobulin G chemistry, Immunoglobulin G toxicity, Lymphocyte Activation drug effects, Macaca fascicularis, Models, Molecular, Neoplasms immunology, T-Lymphocytes, Regulatory drug effects, T-Lymphocytes, Regulatory immunology, Adjuvants, Immunologic pharmacology, Antineoplastic Agents, Immunological pharmacology, CTLA-4 Antigen immunology, Immunoglobulin G pharmacology, Neoplasms therapy
- Abstract
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells. Anti-CTLA-4 antibodies enhance tumor-specific immunity through a variety of mechanisms including: blockade of CD80 or CD86 binding to CTLA-4, repressing regulatory T cell function and selective elimination of intratumoral regulatory T cells via an Fcγ receptor-dependent mechanism. AGEN1884 is a novel IgG1 antibody targeting CTLA-4. It potently enhanced antigen-specific T cell responsiveness that could be potentiated in combination with other immunomodulatory antibodies. AGEN1884 was well-tolerated in non-human primates and enhanced vaccine-mediated antigen-specific immunity. AGEN1884 combined effectively with PD-1 blockade to elicit a T cell proliferative response in the periphery. Interestingly, an IgG2 variant of AGEN1884 revealed distinct functional differences that may have implications for optimal dosing regimens in patients. Taken together, the pharmacological properties of AGEN1884 support its clinical investigation as a single therapeutic and combination agent.
- Published
- 2018
- Full Text
- View/download PDF
5. Retrocyte Display® technology: generation and screening of a high diversity cellular antibody library.
- Author
-
Breous-Nystrom E, Schultze K, Meier M, Flueck L, Holzer C, Boll M, Seibert V, Schuster A, Blanusa M, Schaefer V, Grawunder U, Martin-Parras L, and van Dijk MA
- Subjects
- Animals, Antibodies, Monoclonal genetics, B-Lymphocytes metabolism, Cryopreservation, Drug Evaluation, Preclinical, Flow Cytometry, Genetic Variation, Genetic Vectors, HEK293 Cells, Humans, Immunoglobulin Heavy Chains biosynthesis, Immunoglobulin Heavy Chains genetics, Immunoglobulin Light Chains biosynthesis, Immunoglobulin Light Chains genetics, Immunomagnetic Separation, Peptide Library, Protein Binding, Antibodies, Monoclonal biosynthesis, Retroviridae genetics
- Abstract
Over the last nearly three decades in vitro display technologies have played an important role in the discovery and optimization of antibodies and other proteins for therapeutic applications. Here we describe the use of retroviral expression technology for the display of full-length IgG on B lineage cells in vitro with a hallmark of a tight and stable genotype to phenotype coupling. We describe the creation of a high-diversity (>1.0E09 different heavy- and light-chain combinations) cell displayed fully human antibody library from healthy donor-derived heavy- and light-chain gene libraries, and demonstrate the recovery of high affinity target-specific antibodies from this library by staining of cells with a labeled target antigen and their magnetic- and flow cytometry-based cell sorting. The present technology represents a further evolution in the discovery of full-length, fully human antibodies using mammalian display, and is termed Retrocyte Display® (Retroviral B lymphocyte Display)., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.